
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, explains how capping is measured for mRNA synthesis and how upstream process design shapes downstream purity.
Sponsors who have been lax in performing financial due diligence on their contractors have been given a wake-up call by the recent developments at aaiPharma.
over 22 years ago
In The Spotlight-May 2004over 22 years ago
FDA Eyes Manufacturing Innovation to Boost Drug Developmentover 22 years ago
Prepare for Bar Codingover 22 years ago
Excipient Functionalityover 22 years ago
May 2004




